CROI 2015 Program and Abstracts

Oral Sessions

Session TD-V Themed Discussion

Room 6C

Symposium Conveners Steven Bosinger , Emory University, Yerkes National Primate Research Center Raphael Gottardo , Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, US 171 Using Systems Approaches to Study Pathogenesis: Bridging Networks and Mechanisms Nevan Krogan University of California San Francisco, San Francisco, CA, US 172 Molecular Basis of T-Cell Exhaustion E. JohnWherry University of Pennsylvania, Philadelphia, PA, US 173 A Systems Biology Approach to Identify Targets and Mechanisms of HIV Latency and HIV Eradication Rafick P. Sekaly Case Western Reserve University, Cleveland, OH, US 174 Translating Anti–HIV-1 Immune Mechanisms Into Clinical 4:00 pm– 6:00 pm Scale-Up of Interventions Target audience: This session is directed to researchers and programmers interested in the scale-up of HIV programs around the world. Level of knowledge: It is assumed that participants are familiar with HIV prevention methods, the impact of HIV on key populations, HIV testing approaches, laboratory assays in support of HIV prevention, and HIV care and treatment. Objectives: At the completion of the session, participants will be able to: • Describe scientific evidence relating to male circumcision and its programmatic scale-up for HIV prevention. • Describe scientific bases for interventions for people who inject drugs. • Describe recent evidence and trends concerning scale-up of HIV testing. • Describe the role of laboratory infrastructure and systems required to support HIV/ AIDS program scale-up. Symposium Conveners Prevention Jason B. Reed US Department of State, Office of the Global AIDS Coordinator, Washington, DC, US 176 Scale-Up of HIV Interventions for PeopleWho Inject Drugs: Quality and Coverage Anna Deryabina ICAP at Columbia University, Almaty, Kazakhstan 177 HIV Testing and Counseling: Emerging Issues, New Directions Rachel C. Baggaley World Health Organization, Geneva, Switzerland 178 Ten Years of Strengthening Laboratory Services and Systems: Then, Now, and the Future John Nkengasong US Centers for Disease Control and Prevention, Atlanta, GA, US Linda-Gail Bekker , Desmond Tutu HIV Foundation, South Africa Kevin M. De Cock , Centers for Disease Control and Prevention, Nairobi, Kenya 175 From Equipoise to Efficacy to Millions Reached With Voluntary Medical Male Circumcision for HIV Interventions Sallie R. Permar Duke University, Durham, NC, US Session S-8 Symposium Room 6D

1:30 pm– 2:30 pm PEP: Remember Me? Themed Discussion Leader Kenneth H. Mayer , Fenway Health, Boston, MA, US 959 Tenofovir/Emtricitabine Plus LPV/r vs MVC or Raltegravir for PEP: 2 Randomized Trials Lorna Leal ; Agathe Leon; BertaTorres; Alexy Inciarte; Constanza Lucero; Josep Mallolas; Maria Martinez-Rebollar; Ana González-Cordón; Jose M. Gatell; Felipe Garcia Hospital Clínic Barcelona, Barcelona, Spain 958 Rilpivirine-Emtricitabine-Tenofovir for HIV Nonoccupational Postexposure Prophylaxis Rosalind Foster 1 ; John McAllister 2 ;Tim R. Read 3 ; Anna Pierce 4 ; Robyn Richardson 2 ; Anna McNulty 1 ; Andrew Carr 2 On behalf of the EPEP Study Researchers 1 Sydney Sexual Health Centre, Sydney, Australia; 2 St Vincent’s Centre for Applied Medical Research, Sydney, Australia; 3 Melbourne Sexual Health Centre, Melbourne, Australia; 4 The Alfred Hospital, Melbourne, Australia 957 Significant Intolerability of Efavirenz in HIV Occupational Postexposure Prophylaxis SurasakWiboonchutikul 1 ;VarapornThientong 1 ; Patama Sutha 1 ; Boonchai Kowadisaiburana 2 ;Weerawat Manosuthi 1 1 Bamrasnaradura Infectious Diseases Institute, Nonthaburi, Thailand; 2 Bangkok Hospital, Bangkok, Thailand 961 Management of Acute HIV After Initiation of Postexposure Prophylaxis: Challenges and Lessons Learnt Goli Haidari 1 ; Naomi Fitzgerald 4 ; Sonia Raffe 2 ; Nneka Nwokolo 3 ; Olamide Dosekun 1 ; Mark D. Lawton 5 ; Nickie Mackie 1 ; Julie Fox 4 ; Martin Fisher 2 ; Sarah Fidler 1 1 St Mary’s Hospital–Imperial College Healthcare NHS Trust, London, United Kingdom; 2 Brighton and Sussex Hospitals NHS Trust, Brighton, United Kingdom; 3 Chelsea and Westminster Hospital NHS Foundation Trust, London, United Kingdom; 4 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; 5 The Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, United Kingdom; 6 St Mary’s Hospital–Imperial College Healthcare NHS Trust, London, United Kingdom; 7 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom; 8 Brighton and Sussex Hospitals NHS Trust, Brighton, United Kingdom; 9 St Mary’s Hospital– Imperial College Healthcare NHS Trust, London, United Kingdom 4:00 pm– 6:00 pm From Pathways to Paradigms: Applications of Systems Biology to HIV/Host Interactions Target audience: This session is directed to scientists and clinicians who are interested in recent advances in the use of RNA profiling, transcriptomic analyses, microarrays, and other state-of-the-art methodologies in an integrated approach (ie, systems biology) to probe new insights and hypotheses in HIV and SIV pathogenesis, prevention, and treatment. Level of knowledge: It is assumed that participants are familiar with the basic concepts and challenges in the fields of HIV pathogenesis, prevention, and treatment and have some familiarity with the cellular processes that underlie the molecular biology of viral-host interactions. Objectives: At the completion of the session, participants will be able to: • Recognize how integrative approaches to profiling RNA transcription can be applied to provide new interpretations of relevant problems in HIV pathogenesis research. • Appreciate how a systems-biology approach can generate new hypotheses for developing novel interventions for HIV prevention and therapy. • Discuss emerging technologies and bioinformatics analyses that have enabled molecular signatures and networks to be identified and applied to relevant questions for HIV and other infectious pathogens. Session S-7 Symposium Room 613

Thursday, February 26, 2015 • Oral Sessions

20

CROI 2015